Oncology drugs are clearly the focus of development going into the future, while drugs for infectious disease and central nervous system also make up a large proportion of R&D spend.

Figure 1: Number of pipeline drugs in the US, by therapy area

Source: GlobalData, Pharma Intelligence Center, Drug Database [Accessed 1 November 2017]